New drug cocktail targets tough stomach cancer in Last-Resort patients
NCT ID NCT05905887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—rivoceranib and paclitaxel—in 48 adults with advanced gastrointestinal stromal tumors (GIST) that have a specific protein marker (high P-glycoprotein) and have stopped responding to three standard treatments. The goal is to see if the combo can control the disease. Participants take both drugs daily or weekly in 28-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rivoceranib and paclitaxel
What this could lead to
If successful, this combination could offer a new treatment option for people with a hard-to-treat form of GIST that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial (48 people) with no control group, so results may not apply broadly. The drugs can cause side effects like nerve damage, low blood counts, and high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center, University of Ulsan College of Medicine
RECRUITINGSeoul, Seoul, 138-736, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••